Raymond James Ltd. facilitates $30 million equity financing for Medexus Pharmaceuticals Inc.
Goodmans LLP acted for Raymond James Ltd., as lead underwriter and sole bookrunner, in connection with the $30 million equity financing of Medexus Pharmaceuticals Inc. by way of shelf prospectus offering.
The overnight marketed underwritten offering comprised of 7,500,000 common shares of Medexus at a public offering price of $4.00 per common share. Medexus expects that the net proceeds of the offering will be used: (i) to repay a US$2.5 million credit received from medac in September 2021 and pay a portion of the milestone payment amount to medac, and (ii) for working capital and general corporate purposes, which may include funding the company's ongoing business development activities and initiatives.
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions.
Expertise
Featured Work
-
Capital Markets
CIBC Capital leads C$400 million Oxford Properties Group Trust debt offering
Goodmans LLP acted for CIBC Capital Markets, as Lead Left Joint Bookrunner, and the agents in connection with a C$400 million senior unsecured notes offering for Oxford Properties Group Trust (“OPGT… -
Banking and Finance
Vital Infrastructure Property Trust completes C$300 million senior unsecured debentures offering
Goodmans LLP acted for Vital Infrastructure Property Trust in connection with its private placement offering of C$300 million aggregate principal amount of 4.865% Series C senior unsecured debentures… -
Capital Markets
Apotex Health Corp. closes $1.25 billion inaugural senior unsecured notes offering
Goodmans LLP acted for Apotex Health Corp. in connection with its private placement offering of $1.25 billion aggregate principal amount of senior unsecured notes… -
Entertainment
WildBrain announces a C$20 million substantial issuer bid
Goodmans LLP is acting for WildBrain Ltd. in connection with its substantial issuer bid to purchase, for cancellation, a number of common shares of the company for an aggregate purchase price not… -
Capital Markets
Apotex Health Corp. completes upsized $850 million bought deal secondary offering
Goodmans LLP acted for Apotex Health Corp. in connection with the closing of the upsized bought deal secondary offering of its common shares by an affiliate of SK Capital Partners, API Investment LP… -
Mergers and Acquisitions
Onex Partners and co-investors acquire AirSprint
Goodmans LLP acted as M&A legal counsel to Onex Partners in connection with the acquisition of AirSprint Inc. by Onex and its co-investors…